Evidence map›Paper›PMID 41810472›Full record

ReviewAsian journal of pharmaceutical sciences2026

The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines.

Xuan Lin, Hongguang Xiang, Jiong Wu, Ruixi Liao, Yuhao Li, Bohui Xu, Ying Xu, Yan Shen, Qian Li, Yu Tian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuan LinDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Hongguang XiangDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Jiong WuDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Ruixi LiaoDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yuhao LiDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Bohui XuSchool of Pharmacy, Nantong University, Nantong 226019, China.
Ying XuCollege of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Yan ShenDepartment of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Qian LiSchool of Life Science & Technology, China Pharmaceutical University, Nanjing 210009, China.
Yu TianSchool of Medicine, Shanghai University, Shanghai 200444, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid-based therapies have emerged as promising strategies for the regulation of gene expression and the production of therapeutic antigens or proteins for a series of diseases, including cancers, rare diseases, and infectious diseases. However, their clinical application faces challenges. These include high molecular weight, limited cellular uptake, and susceptibility to enzymatic degradation by nucleases

Indexed as

Delivery systemsLipid nanoparticle carriersNucleic acid delivery challengesNucleic acid drugsNucleic acid therapeutics

Identifiers

PMID41810472
PMCPMC12907873

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.